CAJ | 학술논문

目的：探讨艾迪注射液联合多西他赛、卡铂方案对非小细胞肺癌的临床疗效及作用机制。方法将70例非小细胞肺癌患者随机分为观察组35例和对照组35例。对照组采用多西他赛、卡铂方案，观察组在对照组基础上联合艾迪注射液。比较2组患者临床疗效、生存质量、不良反应发生情况，并记录2组患者治疗前后血清可溶性白介素2受体（SIL-2R）、癌胚抗原（CEA）和血管内皮生长因子（VEGF）水平。结果观察组总有效率为31．43％，临床受益率为94．29％；对照组总有效率为28．57％，临床受益率为85．71％。组间临床疗效相比，差异无统计学意义（χ2＝0．195，P＝0．659）；观察组临床受益率显著高于对照组（χ2＝4．089，P＝0．043）。观察组生理功能、情感功能、社会功能得分显著提高，疲劳，疼痛，恶心呕吐得分显著优于对照组（P＜0．05）；治疗后2组患者血清SIL-2R、CEA、VEGF水平均显著降低（P＜0．05），其中观察组SIL-2R、CEA、VEGF水平显著低于对照组（P＜0．05）。2组患者主要不良反应包括骨髓抑制（白细胞减少、血小板减少）、消化道反应（恶心、呕吐、腹泻）和口腔黏膜炎等，其中观察组血小板减少发生率显著低于对照组（χ2＝8．363，P＝0．004）。结论艾迪注射液能够提高非小细胞肺癌患者生存质量，降低不良反应发生，可以作为非小细胞肺癌化疗的一种重要辅助用药。
목적：탐토애적주사액연합다서타새、잡박방안대비소세포폐암적림상료효급작용궤제。방법장70례비소세포폐암환자수궤분위관찰조35례화대조조35례。대조조채용다서타새、잡박방안，관찰조재대조조기출상연합애적주사액。비교2조환자림상료효、생존질량、불량반응발생정황，병기록2조환자치료전후혈청가용성백개소2수체（SIL-2R）、암배항원（CEA）화혈관내피생장인자（VEGF）수평。결과관찰조총유효솔위31．43％，림상수익솔위94．29％；대조조총유효솔위28．57％，림상수익솔위85．71％。조간림상료효상비，차이무통계학의의（χ2＝0．195，P＝0．659）；관찰조림상수익솔현저고우대조조（χ2＝4．089，P＝0．043）。관찰조생리공능、정감공능、사회공능득분현저제고，피로，동통，악심구토득분현저우우대조조（P＜0．05）；치료후2조환자혈청SIL-2R、CEA、VEGF수평균현저강저（P＜0．05），기중관찰조SIL-2R、CEA、VEGF수평현저저우대조조（P＜0．05）。2조환자주요불량반응포괄골수억제（백세포감소、혈소판감소）、소화도반응（악심、구토、복사）화구강점막염등，기중관찰조혈소판감소발생솔현저저우대조조（χ2＝8．363，P＝0．004）。결론애적주사액능구제고비소세포폐암환자생존질량，강저불량반응발생，가이작위비소세포폐암화료적일충중요보조용약。
Objective To explore the the clinical efficacy and serum SIL-2R,CEA,VEGF level changes of addie injec-tion combined with docetaxel and carboplatin for non-small cell lung cancer (NSCLC).Methods 70 cases of NSCLC were ran-domly divided into the experimental group and the control group ,each with 35 cases.The control group received docetaxel and car-boplatin,the experimental group received addie injection based on the control group .Clinical efficacy,quality of life and adverse reactions of the 2 groups were compared ,and serum SIL-2R,CEA,VEGF levels of the 2 groups before and after treatment were re-corded.Results In the experimental group ,the total effective rate was 31.43%,the clinical benefit rate was 94.29%; in the control group,the total effective rate was 28.57%,the clinical benefit rate was 85.71%,there had no significant difference in clinical efficacy between the 2 groups (χ2 =0.195,P=0.659),the clinical benefit rate of the experimental group was significant-ly higher than that of the control group (χ2 =4.089,P=0.043).Serum SIL-2R,CEA,VEGF levels of the 2 groups after treat-ment were significantly lower ,and those of the experimental group were significantly lower than those of the control group ( P<0.05).Physiological function,emotional function and social function scores in the experimental group after treatment improved significantly,fatigue,pain,nausea and vomiting in the experimental group were superior to the control group ( P<0.05); main adverse reactions of the 2 groups were bone marrow suppression ( leukopenia ,thrombocytopenia ) ,gastrointestinal reactions ( nau-sea,vomiting,diarrhea)and oral mucositis.Thrombocytopenia in the experiment group was significantly lower than that of the con -trol group (χ2 =8.363,P=0.004).Conclusion Addie injection for NSCLC can improve quality of life ,reduce adverse reac-tions,and it can be used as an important adjuvant chemotherapy for NSCLC .